BioInformant

Your Global Leader in Stem Cell Market Research

CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®

By Leave a Comment

Program provides free cord blood and tissue processing to qualifying families in need.

TRUMBULL, Conn., Jan. 5, 2023 — CooperSurgical, a global leader in fertility and women’s health, shared that more than 11,000 families have enrolled in the Newborn Possibilities Program® through their Cord Blood Registry® (CBR®) brand. Through the Newborn Possibilities Program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. [Read more…]

How to find the right end-to-end developer for manufacturing your cGMP-compatible iPSCs

By Leave a Comment

Introduction

From β-islets for diabetes (1) to dopaminergic neurons (Figure 1) for Parkinson’s disease (2), induced pluripotent stem cell (iPSC)-derived, haplotyped, and multiplex-engineered allogeneic cell therapeutics empower the development of effective and safe Cell and Gene Therapy Products (CGTs) that could be manufactured on a large scale in a cost-effective manner and provide a functional cure for diseases that plague humankind today. [Read more…]

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

By Leave a Comment

Newark, New Jersey, January 17, 2022 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.

[Read more…]

70% of Global Cord Blood Market Controlled by World’s 12 Largest Operators

By Leave a Comment

For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities. Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk pace, indicating a promising future for the industry.

Given the operational efficiencies associated with market consolidation, the global cord blood and tissue banking market is being consolidated by a handful of large and well capitalized market competitors. [Read more…]

Sernova and Evotec on Track to Initiate Clinical Testing of First iPSC-Derived Islets as a Potential Functional Cure for Type 1 Diabetes

By Leave a Comment

  •  First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia
  • iPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluation
  • T1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated consistent long-term insulin independence de-risking the combined technologies for both companies

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0